Nimotop S (Nimodipine)

Nimodipine, the active ingredient in Nimotop S, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, improving cerebral blood flow in affected patients and may contribute to neurological recovery.

GNH USA supplies Nimotop S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company adheres to stringent manufacturing standards and provides reliable logistics for global distribution.

Nimodipine is a calcium channel blocker used primarily in the management of cerebrovascular complications.

- Prevention of cerebral vasospasm following subarachnoid hemorrhage: reduces the risk of delayed ischemic neurological deficits by promoting cerebral vasodilation. - Aneurysmal subarachnoid hemorrhage after surgical repair: helps prevent delayed vasospasm and supports recovery. - Acute neurological injury with risk of cerebral ischemia: used as adjunctive therapy to improve cerebral blood flow.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with reddening of skin. - Dizziness: sensation of light‑headedness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring medical attention. - Bradycardia: unusually slow heart rate. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reaction: rash, itching, or swelling. - Neutropenia: low white‑blood‑cell count. - Myocardial infarction: rare cardiac event.

Before initiating therapy, clinicians should consider several safety aspects.

- Monitor blood pressure: watch for symptomatic hypotension. - Assess liver function: adjust use in hepatic impairment. - Avoid strong CYP3A4 inhibitors: may increase nimodipine plasma levels. - Use caution in elderly patients: increased sensitivity to vasodilatory effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Nimodipine can interact with other medicines that affect cardiovascular tone or metabolism.

Major Interactions (Avoid): - Concurrent use with other potent vasodilators: risk of severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations. - Combined use with beta‑blockers: additive cardiovascular depression.

Moderate Interactions (Monitor Closely): - Co‑administration with other calcium channel blockers (e.g., amlodipine): monitor blood pressure. - Diuretics: may enhance hypotensive effect. - Other antihypertensive agents: dose adjustments may be required.